Keryx Biopharmaceuticals (NASDAQ:KERX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.


Player Avatar mdriver78 (61.69) Submitted: 1/3/2013 9:23:29 AM : Underperform Start Price: $2.68 KERX Score: -77.76

Congress added language to delay by two years the implementation of oral-only end-stage renal disease (ESRD) related drugs, including phosphate binders, in the bundled ESRD prospective payment system, until January 1, 2016. Affecting medicare coverage of the drug use.

Featured Broker Partners